Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:00 AM — Educational Meeting
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California
Meeting Room
Seaport A-D (Second Level)
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.
Faculty Professor Andreas Hochhaus
Hematology/Oncology
Jena University Hospital
Comprehensive Cancer Center Central Germany Campus Jena
Jena, Germany
B Douglas Smith, MD
Professor, Oncology Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Moderator Michael J Mauro, MD
Director, Chronic Myeloid Leukemia Program
Attending Physician, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
This activity is supported by an educational grant from Novartis.
Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:00 AM — Educational Meeting
Clinical and biological factors (eg, patient age, comorbidities, Sokal risk score) influencing the selection of front-line treatment for chronic-phase (CP) CML
Pharmacologic similarities and differences among imatinib, dasatinib, nilotinib and bosutinib; implications for the efficacy and tolerability of these agents
Long-term efficacy outcomes observed with approved first- and second-generation tyrosine kinase inhibitors (TKIs) for patients with newly diagnosed CP-CML
Mechanism of action of asciminib; similarities and differences with TKIs employed in the management of CML
Key efficacy findings from the Phase III ASC4FIRST trial evaluating asciminib versus standard first-line TKIs for patients with newly diagnosed CP-CML
Recent FDA approval of asciminib for newly diagnosed CP-CML; current role in this setting
Biological rationale for combining asciminib with TKI therapy; ongoing investigation of combination strategies for previously untreated CP-CML
MODULE 2: Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro
Mechanisms of TKI resistance; role of gene expression profiling in informing therapeutic selection in this setting
Incidence and clinical relevance of the BCR::ABL1 T315I mutation in patients with CML; biological rationale for the activity of ponatinib and asciminib in CML with a T315I mutation
Key efficacy and safety findings supporting the use of ponatinib for patients with CP-CML with resistance or intolerance to at least 2 prior TKIs or with a T315I mutation
Major outcomes from the Phase III ASCEMBL trial investigating asciminib versus bosutinib for previously treated CP-CML
Available data with asciminib for CML with a T315I mutation
FDA approval of asciminib for CP-CML previously treated with 2 or more TKIs or with a T315I mutation; optimal use in clinical practice
Other promising investigational agents and strategies for CML
MODULE 3: Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith
Spectrum, frequency and severity of class-effect and agent-specific toxicities documented with first-, second- and third-generation TKIs for CML; implications for the selection of a specific TKI in up-front and later-line settings
Tolerability and toxicity profile of asciminib for patients with CML
Optimal monitoring and management of treatment-related adverse events with TKIs and asciminib
Other practical considerations (eg, concomitant medications, dosing, dose adjustments) in the application of TKIs and asciminib for CML
Available data on the feasibility of TKI discontinuation for patients who experience sustained response to treatment; identification of appropriate candidates for this strategy
Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic myeloid leukemia (CML).
Learning Objectives
Upon completion of this activity, participants should be able to
Evaluate factors, including age, comorbidities, personal preferences and side-effect profile, that contribute to the selection and sequencing of therapies for chronic-phase (CP) CML, and counsel patients regarding personalized treatment recommendations.
Assess pharmacologic similarities and differences among tyrosine kinase inhibitors available for the treatment of CML, and identify which agent is optimal for patients at each stage of the disease course.
Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for CML, and appreciate the current role of these agents for patients with relapsed/refractory disease.
Consider the biological rationale for and available research findings with STAMP inhibitors as initial treatment for newly diagnosed CP-CML, and recognize the current role of this novel therapeutic strategy.
Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with agents commonly employed in the care of patients with CML to support quality of life and continuation of treatment.
CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR — Dr Mauro — Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Enliven Therapeutics, Novartis, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Enliven Therapeutics, Novartis, Terns Pharmaceuticals, Sun Pharma Advanced Research Company (SPARC), Sun Pharmaceutical Industries Ltd.
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by an educational grant from Novartis.
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Meeting Room
Seaport A-D (Second Level)
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic myeloid leukemia.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
